Good Morning Meeting | Generalized Pairwise Comparisons (GPC): An innovative statistical method to design and analyze clinical trials
In collaboration with MVA, IDDI team is pleased to invite you to
a Good Morning Meeting
COPENHAGEN, DENMARK | APRIL 21 – 09:00 – 11:00 am CET
Learn on an innovative statistical method – Generalized Pairwise Comparisons (GPC) used to design and analyze clinical trials to make the best possible use of the data collected.
Generalized Pairwise Comparison (GPC) is an innovative statistical method used to design and analyze clinical trials to make the best possible use of the data collected. This allows the analysis to take into account several endpoints, providing deeper insights into the net treatment benefits. Specifically, the GPC method enables you to:
- Assess clinical trials based on multiple endpoints leading to increased power
- Conduct meaningful risk: benefit analyses
Generalized pairwise comparisons (GPC) is a novel statistical approach to the analysis of randomized trials, based on comparisons of every possible pair formed by one patient from the experimental arm and one from the control arm. Since the GPC method can formally handle several endpoints simultaneously, it is a versatile approach to various situations that arise in drug development, such as the need to prioritize among different endpoints and to conduct meaningful risk: benefit analyses. Moreover, the use of GPC generally leads to increased power, something advantageous in various settings, including rare diseases. The results from GPC are summarized by measures of treatment effect that jointly indicate probabilities of improved outcomes. Such measures include the Net Treatment Benefit, the Win Ratio, and the Win Odds, and they can all be used in a personalized manner if the endpoints to be analyzed are ranked in an order of priority that is clinically meaningful. In this seminar, we will describe how the GPC method can be used to design and analyze clinical trials and make the best possible use of the data collected.
During this presentation, the participant will:
– Understand how this method can be used to evaluate multiple endpoints
– Identify how this method can be used to evaluate multiple endpoints
– Gain insights into how this approach will ultimately lead to truly “patient-centric medicine”
Vaiva Deltuvaite-Thomas, MS, Research Biostatistician, IDDI
DOWNLOAD THE PRESENTATION: